Ancaster, Canada, May 14, 2016 --(PR.com
)-- For too many years, hemostasis research and treatments for patients in emerging countries were overlooked in favor of further development for the seven major markets. In an interview with the ISTH Congress, SSC Meeting President Jean-François Schved acknowledged the problem and promised the SSC would emphasize the unique conditions medical professionals face in emerging countries. Schved said, "An important part of the program will focus on the possibilities for physicians or biologists in emerging countries to develop methods of care" and also noted the contributions doctors and researchers have made in those areas.
In addition to the discussion of emerging countries, the SSC will include several informational sessions about new hemostasis research, and new drugs in the approval pipeline. Sam Schulman and Andreas Greinacher will examine controversies surrounding oral anti-coagulants. Nigel Key and Robert Medcalf will deliver an overview of the newest treatment options. Roundtable discussions of critical issues in the field of thrombosis and hemostasis research will fill the afternoon and evening hours, creating a full slate of events for attendees.
For Affinity Biologicals, the conference is a chance to meet face-to-face with the international clients who utelize Affinity Biologicals' products their research.
About Affinity Biologicals
Affinity Biologicals is the manufacturer of numerous products used in thrombosis and hemostasis research and diagnostic testing. Affinity Biologicals offers a diverse line research products and diagnostic test products, including antibody and ELISA test kits, as well as immuno-depleted plasmas and matched pair antibodies.
For more information, please visit www.affinitybiologicals.com or call (905) 304-9896.